


Linifanib (GMP)

| | |
|--------------------|---|
| Cat. No.: | HY-50751G |
| CAS No.: | 796967-16-3 |
| Molecular Formula: | C ₂₁ H ₁₈ FN ₃ O |
| Molecular Weight: | 375.4 |
| Target: | VEGFR; PDGFR |
| Pathway: | Protein Tyrosine Kinase/RTK |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC ₅₀ s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells ^[1] . |
| IC₅₀ & Target | IC ₅₀ : 4 nM (KDR), 4 nM (FLT1), 66 nM (PDGFRβ), 3 nM (CSF-1R), 4 nM (FLT3), 14 nM (Kit) ^[1] |
| In Vitro | Linifanib (GMP) (1 μM) induces generation of hCiPS cells from human embryonic fibroblasts (HEFs) ^[1] . Linifanib (GMP) (1 μM) induces generation of hCiPS cells from hADSCs or hASFs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

CUSTOMER VALIDATION

- Nat Biomed Eng. 2018 Aug;2(8):578-588.
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Int J Oncol. 2019 Oct;55(4):879-895.
- Harvard Medical School LINCS LIBRARY

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Guan J, et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022 May;605(7909):325-331.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA